IDO1 and melanoma: Moreover, recent studies have demonstrated that PPAR could enhance indoleamine 2,3-dioxgenase-1 (IDO) activity and promote the generation of regulatory T cells in melanoma; hence, the use of PPAR inhibitors could enhance cancer immunotherapy (Poupot et al., 2014).